Evidence mapPaperPMID 33560411Full record

Trial reportThe international journal of neuropsychopharmacology2021

Neuroendocrine Response to Exogenous Ghrelin Administration, Combined With Alcohol, in Heavy-Drinking Individuals: Findings From a Randomized, Double-Blind, Placebo-Controlled Human Laboratory Study.

Mehdi Farokhnia, Kelly M Abshire, Aaron Hammer, Sara L Deschaine, Anitha Saravanakumar, Enoch Cobbina, Zhi-Bing You, Carolina L Haass-Koffler, Mary R Lee, Fatemeh Akhlaghi and 1 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The international journal of neuropsychopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Current View on the Mechanisms of Alcohol-Mediated Toxicity.International journal of molecular sciences · 2021
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Mehdi FarokhniaClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
Kelly M AbshireClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
Aaron HammerClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
Sara L DeschaineClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
Anitha SaravanakumarClinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island.
Enoch Cobbina
Zhi-Bing YouMolecular Targets and Medications Discovery Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Baltimore, Maryland, USA.
Carolina L Haass-KofflerClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.ORCID 0000-0002-5634-5679
Mary R LeeClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
Fatemeh AkhlaghiClinical Pharmacokinetics Research Laboratory, Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, Rhode Island.
Lorenzo LeggioClinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore and Bethesda, Maryland, USA.
National Institute on Drug Abuse · USNational Institutes of Health · USUniversity of Rhode Island · US

Funding

RAT RESEARCH COMPONENTP50AA007611 · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · 1987 to 2002
$5.3M
ALCOHOL INTERVENTION/TREATMENT OUTCOME RESEARCH TRAININGT32AA007459 · BROWN UNIVERSITY · 1986 to 2025
$3.6M
Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN)ZIADA000635 · NATIONAL INSTITUTE ON DRUG ABUSE · 2025 to 2025
$2.7M
Using wearables and EMA to examine the links between cannabis and depressionP20GM130414 · BROWN UNIVERSITY · 2025 to 2025
$2.3M
A focus on alpha-1 blockade as a novel pharmacological treatment for alcohol use disorderR01AA027760 · NIAAA · BROWN UNIVERSITY · PI Carolina Luisa Haass-Koffler · 2023 to 2023
$448k
Intramural NIH HHS ZIA AA000218Intramural NIH HHS ZIA DA000635NIAAA NIH HHS K01 AA023867NIAAA NIH HHS P50 AA007611NIAAA NIH HHS R01 AA026589NIAAA NIH HHS R01 AA027760NIAAA NIH HHS R21 AA027614NIAAA NIH HHS T32 AA007459NIGMS NIH HHS P20 GM130414
6 · The paper itself

Abstract

backgroundAccumulating evidence has established a role for the orexigenic hormone ghrelin in alcohol-seeking behaviors. Accordingly, the ghrelin system may represent a potential pharmacotherapeutic target for alcohol use disorder. Ghrelin modulates several neuroendocrine pathways, such as appetitive, metabolic, and stress-related hormones, which are particularly relevant in the context of alcohol use. The goal of the present study was to provide a comprehensive assessment of neuroendocrine response to exogenous ghrelin administration, combined with alcohol, in heavy-drinking individuals.

methodsThis was a randomized, crossover, double-blind, placebo-controlled human laboratory study, which included 2 experimental alcohol administration paradigms: i.v. alcohol self-administration and i.v. alcohol clamp. Each paradigm consisted of 2 counterbalanced sessions of i.v. ghrelin or placebo administration. Repeated blood samples were collected during each session, and peripheral concentrations of the following hormones were measured: leptin, glucagon-like peptide-1, pancreatic polypeptide, gastric inhibitory peptide, insulin, insulin-like growth factor-1, cortisol, prolactin, and aldosterone.

resultsDespite some statistical differences, findings were consistent across the 2 alcohol administration paradigms: i.v. ghrelin, compared to placebo, increased blood concentrations of glucagon-like peptide-1, pancreatic polypeptide, cortisol, and prolactin, both acutely and during the whole session. Lower levels of leptin and higher levels of aldosterone were also found during the ghrelin vs placebo session.

conclusionThese findings, gathered from a clinically relevant sample of heavy-drinking individuals with alcohol use disorder, provide a deeper insight into the complex interplay between ghrelin and appetitive, metabolic, and stress-related neuroendocrine pathways in the context of alcohol use.

Indexed as

AdultAlcohol DrinkingAlcoholismCentral Nervous System DepressantsCravingDouble-Blind MethodEthanolFemaleGhrelinHumansMaleMiddle AgedNeurosecretory SystemsSelf AdministrationCentral Nervous System DepressantsEthanolGhrelinalcoholGhrelinmetabolismneuroendocrinestress

Identifiers

PMID33560411
PMCPMC8278796
OpenAlexW3127017427

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.